文献速递甲状腺疾病

激肽释放酶逐步评分揭示甲状腺乳头状癌三种预后相关亚型

Kallikreins Stepwise Scoring Reveals Three Subtypes of Papillary Thyroid Cancer with Prognostic Implications.
PubMed 文献 · Thyroid · 2018-01-01

研究分析四个已发表甲状腺癌数据集的DNA甲基化、基因表达及BRAF/RAS突变,用C4.5决策树构建基于三种激肽释放酶的算法,以>80%灵敏度和>95%特异度识别BRAF和RAS突变肿瘤,并发现一种预后良好的新亚型。

要点

  • 激肽释放酶家族在甲状腺乳头状癌中普遍失调,表观遗传和转录谱与BRAF V600E或RAS突变强相关。
  • 基于三种激肽释放酶的决策树算法识别BRAF和RAS突变肿瘤的灵敏度>80%、特异度>95%。
  • 该算法发现一种具有良好预后特征的新甲状腺乳头状癌亚型。

核心结论

  • 激肽释放酶算法可能成为甲状腺乳头状癌风险分层和患者管理的新临床适用策略。

研究设计与样本

  • 研究分析四个已发表甲状腺癌数据集的DNA甲基化(HumanMethylation芯片)和基因表达(RNA-Seq)、BRAF和RAS突变及临床数据,样本量分别为n=73、n=475、n=20和n=82,作为发现、训练和验证系列。
  • 使用C4.5分类算法生成决策树,采用Kaplan-Meier和Cox方法估计无病生存,并用实时聚合酶链反应和免疫组化进行特异性分析。

主要发现

  • 整个激肽释放酶家族在甲状腺乳头状癌中失调,呈现与BRAF V600E或RAS突变强相关的特异性表观遗传和转录谱。
  • 基于三种激肽释放酶的决策树算法识别BRAF和RAS突变肿瘤的灵敏度>80%、特异度>95%。
  • 缺乏这些突变的肿瘤被分类为BRAF样或RAS样。
  • 激肽释放酶算法揭示了一种具有良好预后特征的新甲状腺乳头状癌亚型。

临床怎么用

  • 作者认为激肽释放酶算法可能成为甲状腺乳头状癌风险分层和患者管理的新临床适用策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer. Unlike most cancers, its incidence has dramatically increased in the last decades mainly due to increased diagnosis of indolent PTCs. Adequate risk stratification is crucial to avoid the over-treatment of low-risk patients, as well as the under-treatment of high-risk patients, but the currently available markers are still insufficient. Kallikreins (KLKs) are emergent biomarkers in cancer, but their involvement in PTC is unknown. METHODS: This study analyzed DNA methylation (HumanMethylation arrays) and gene expression (RNA-Seq) of KLKs, BRAF and RAS mutations, and clinical data from four published thyroid cancer data sets including normal and tumor tissues (n = 73, n = 475, n = 20, and n = 82) as discovery, training, and validation series. The C4.5 classification algorithm was used to generate a decision tree. Disease-free survival was estimated using Kaplan-Meier and Cox approaches. Specific analyses were performed using real-time polymerase chain reaction and immunohistochemistry. RESULTS: The entire KLK family was deregulated in PTC, displaying a specific epigenetic and transcriptional profile strongly associated with BRAFV600E or RAS mutations. Thus, a decision-tree algorithm was developed based on three KLKs with >80% sensitivity and >95% specificity, identifying BRAF- and RAS-mutated tumors. Notably, tumors lacking these mutations were classified as BRAF- or RAS-like. Most importantly, the KLK algorithm uncovered a novel PTC subtype showing favorable prognostic features. CONCLUSIONS: The KLK algorithm could lead to a new clinically applicable strategy with important implications for the risk stratification of PTC and the management of patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Buj R, Mallona I, Díez-Villanueva A, et al. Kallikreins Stepwise Scoring Reveals Three Subtypes of Papillary Thyroid Cancer with Prognostic Implications. Thyroid. 2018. PMID: 29635968. doi:10.1089/thy.2017.0501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。